Harbinger Times

(Albany, New York) – October 19, 2026 – The market dynamics for diabetic nephropathy, also known as diabetic kidney disease (DKD), are expected to witness steady growth driven by the rising burden of diabetes, increasing demand for therapies that slow kidney disease progression, and growing adoption of treatments that provide renal and cardiovascular protection. Additionally, the development of emerging therapies such as esaxerenone (Daiichi Sankyo), SER150 (Serodus), zibotentan in combination with dapagliflozin (AstraZeneca), BI 690517 (Boehringer Ingelheim), and other candidates is expected to influence the market in the coming years.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Diabetic Nephropathy/Diabetes Kidney Disease Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of diabetic nephropathy, including historical and forecasted epidemiology, market trends, emerging therapies, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Diabetic Nephropathy Market

• The diabetic kidney disease market across the seven major markets (7MM) was valued at approximately USD 8.8 billion in 2025 and is projected to grow at a CAGR of approximately 5% from 2026 to 2036.

• The United States accounted for the largest share of the DKD market among the 7MM in 2025.

• Germany held the largest DKD market among the EU4 and the United Kingdom in 2025, followed by Italy.

• The market is increasingly driven by the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (MRAs), alongside established renin–angiotensin–aldosterone system (RAAS) inhibitors.

• In 2025, antidiabetic drugs generated the highest revenue among the treatment categories assessed across the 7MM.

• Key companies in the diabetic nephropathy treatment landscape include Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, Daiichi Sankyo, Serodus, Palatin Technologies, Novo Nordisk, and others.

• Prominent therapies assessed in the market include Jardiance (empagliflozin), Farxiga/Forxiga (dapagliflozin), Kerendia (finerenone), esaxerenone, SER150, zibotentan plus dapagliflozin, atrasentan, BI 690517, and INV-202.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/diabetic-nephropathy-market

Key Factors Driving the Diabetic Nephropathy Market

Rising Prevalence of Diabetes and Diabetic Kidney Disease: The growing burden of diabetes is a major driver of the diabetic nephropathy market. Persistent high blood glucose levels can damage the kidneys over time, increasing the risk of albuminuria, declining kidney function, chronic kidney disease, and kidney failure. Early screening and improved management of diabetes are increasing the need for long-term renal-protective treatment.

Increasing Demand for Kidney-Protective Therapies: Treatment strategies increasingly focus on slowing kidney disease progression and reducing cardiovascular complications. SGLT2 inhibitors such as empagliflozin and dapagliflozin have become important treatment options because of their kidney and cardiovascular benefits. Their adoption is contributing to changes in clinical practice and the competitive landscape.

Growing Adoption of Non-steroidal Mineralocorticoid Receptor Antagonists: Finerenone (Kerendia) has expanded treatment options for eligible patients with chronic kidney disease associated with type 2 diabetes. By targeting mineralocorticoid receptor overactivation, finerenone helps reduce the risk of kidney and cardiovascular complications. Continued research into other MRAs, including esaxerenone, may further influence future treatment strategies.

Advancements in Emerging Therapies: Pharmaceutical companies are investigating novel agents targeting inflammation, fibrosis, metabolic pathways, and other mechanisms involved in diabetic kidney disease. Emerging candidates include zibotentan plus dapagliflozin, BI 690517, atrasentan, and INV-202. These candidates are at different stages of development, and their future role will depend on clinical results and regulatory outcomes.

Growing Focus on Early Intervention and Personalized Treatment: Earlier identification of kidney damage through estimated glomerular filtration rate (eGFR) assessment and urine albumin-to-creatinine ratio testing can support timely intervention. Treatment increasingly combines glucose management, blood pressure control, RAAS inhibitors, SGLT2 inhibitors, and other appropriate therapies according to individual patient characteristics and clinical guidelines.

Diabetic Nephropathy Competitive Landscape

Several pharmaceutical companies are developing and commercializing therapies intended to slow kidney disease progression and reduce cardiovascular risk in patients with diabetic kidney disease.

Key companies and therapies include:

• Boehringer Ingelheim/Eli Lilly: Jardiance (empagliflozin)

• Bayer: Kerendia (finerenone)

• AstraZeneca: Farxiga/Forxiga (dapagliflozin) and zibotentan plus dapagliflozin

• Daiichi Sankyo: Esaxerenone (Minnebro)

• Serodus: SER150

• Palatin Technologies: Bremelanotide (Vyleesi)

• Novartis/Chinook Therapeutics: Atrasentan

• Boehringer Ingelheim: BI 690517

• Novo Nordisk/Inversago Pharma: INV-202

Established therapies such as SGLT2 inhibitors and finerenone are helping shape current treatment practice, while investigational agents are exploring additional mechanisms to address residual kidney and cardiovascular risk. The development status and clinical relevance of each candidate vary, and not every drug listed is approved specifically for diabetic nephropathy.

Discover more about therapies set to grab major diabetic nephropathy market share @ Diabetic Nephropathy Treatment Landscape.

Recent Developments in the Diabetic Nephropathy Market

• January 2026: A review published in Nature Reviews Nephrology highlighted next-generation therapeutic approaches for diabetic kidney disease, including incretin-based therapies, endothelin receptor antagonists, aldosterone synthase inhibitors, soluble guanylate cyclase agonists, and anti-inflammatory agents.

• Ongoing clinical development: Research continues to evaluate combinations of kidney-protective therapies, including zibotentan plus dapagliflozin and BI 690517 plus empagliflozin, to improve renal outcomes and address residual cardiorenal risk.

• Expansion of targeted treatment options: The adoption of SGLT2 inhibitors and non-steroidal MRAs is changing the treatment landscape, with growing emphasis on combining therapies that address different mechanisms of disease progression.

What Is Diabetic Nephropathy?

Diabetic nephropathy, commonly referred to as diabetic kidney disease (DKD), is a complication of diabetes that damages the kidneys over time. Persistent elevated blood glucose levels, high blood pressure, inflammation, and changes in kidney blood flow can impair the kidneys’ ability to filter waste and regulate fluid balance.

The condition may initially develop without noticeable symptoms. As it progresses, patients may develop albuminuria, declining kidney function, chronic kidney disease, and, in severe cases, kidney failure. DKD is also associated with an increased risk of cardiovascular complications.

Treatment focuses on glucose and blood pressure management, lifestyle modifications, and therapies that protect kidney and cardiovascular function. Common treatment approaches include RAAS inhibitors, SGLT2 inhibitors, non-steroidal MRAs such as finerenone, and other appropriate diabetes therapies. Emerging treatments are being investigated to further reduce disease progression and address residual cardiovascular and renal risks.

Diabetic Nephropathy Epidemiology Segmentation

The diabetic nephropathy epidemiology section provides insights into the historical and current patient population, along with forecasted trends across the 7MM. The report evaluates disease burden and patient characteristics over the study period 2022–2036, segmented into:

• Total Prevalent Cases of Diabetic Kidney Disease

• Diagnosed Prevalent Cases of Diabetic Kidney Disease

• Age-specific Cases of Diabetic Kidney Disease

• Stage-specific Cases of Diabetic Kidney Disease

According to DelveInsight’s analysis, the burden of diabetic kidney disease is higher among individuals aged 60 years and older than among those aged 18–59 years, reflecting the association between disease progression, aging, and long-standing diabetes. The report also examines geographical differences in patient populations and forecasts future treatment needs across the United States, EU4 and the United Kingdom, and Japan.

Scope of the Diabetic Nephropathy Market Report

• Therapeutic Assessment: Current marketed and emerging diabetic nephropathy therapies.

• Market Dynamics: Key market drivers, barriers, forecast assumptions, and future market outlook.

• Key Companies: Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, Daiichi Sankyo, Serodus, Palatin Technologies, Novo Nordisk, and others.

• Key Therapies: Jardiance, Farxiga/Forxiga, Kerendia, esaxerenone, SER150, zibotentan plus dapagliflozin, atrasentan, BI 690517, and INV-202.

• Competitive Intelligence Analysis: Assessment of treatment classes, clinical development, market competition, and potential market opportunities.

• Unmet Needs and Market Access: Treatment challenges, key opinion leader insights, reimbursement considerations, and future therapeutic opportunities.

To know more about diabetic nephropathy companies working in the treatment market, visit @ Diabetic Nephropathy Clinical Trials and Therapeutic Assessment.

Table of Contents

1. Diabetic Nephropathy Market Report Introduction

2. Executive Summary for Diabetic Nephropathy

3. SWOT Analysis of Diabetic Nephropathy

4. Diabetic Nephropathy Patient Share Overview at a Glance

5. Diabetic Nephropathy Market Overview at a Glance

6. Diabetic Nephropathy Background and Overview

7. Diabetic Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Nephropathy

9. Diabetic Nephropathy Current Treatment and Medical Practices

10. Diabetic Nephropathy Unmet Needs

11. Diabetic Nephropathy Emerging Therapies

12. Diabetic Nephropathy Market Outlook

13. Country-Wise Diabetic Nephropathy Market Analysis (2022–2036)

14. Diabetic Nephropathy Market Access and Reimbursement of Therapies

15. Diabetic Nephropathy Market Drivers

16. Diabetic Nephropathy Market Barriers

17. Diabetic Nephropathy Appendix

18. Diabetic Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/